Odyssey Therapeutics (NASDAQ:ODTX) Upgraded at UBS Group

by · The Markets Daily

Odyssey Therapeutics (NASDAQ:ODTX – Get Free Report) was upgraded by analysts at UBS Group to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks reports.

Several other research firms have also recently issued reports on ODTX. Oppenheimer reissued an “outperform” rating and set a $40.00 price target on shares of Odyssey Therapeutics in a report on Thursday, June 18th. Weiss Ratings started coverage on shares of Odyssey Therapeutics in a report on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. JPMorgan Chase & Co. lifted their price objective on Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Raymond James Financial initiated coverage on Odyssey Therapeutics in a research report on Thursday, October 8th. They issued an “outperform” rating and a $42.00 price target for the company. Finally, HC Wainwright initiated coverage on Odyssey Therapeutics in a research report on Thursday, August 27th. They set a “buy” rating and a $44.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.33.

Check Out Our Latest Research Report on ODTX

Odyssey Therapeutics Trading Down 5.6%

ODTX opened at $17.24 on Monday. Odyssey Therapeutics has a 52 week low of $15.10 and a 52 week high of $29.05. The stock’s 50 day moving average price is $22.71.

Odyssey Therapeutics (NASDAQ:ODTX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. Equities analysts predict that Odyssey Therapeutics will post -6.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Odyssey Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ODTX. Citadel Advisors LLC acquired a new position in shares of Odyssey Therapeutics during the second quarter worth $4,162,000. State Street Corp purchased a new stake in shares of Odyssey Therapeutics during the second quarter worth about $1,477,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Odyssey Therapeutics during the 2nd quarter valued at approximately $601,000.

Odyssey Therapeutics Company Profile

(Get Free Report)

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for serious diseases, with an emphasis on immunology and oncology. The company uses a combination of human genetics, functional genomics, computational biology, machine learning and medicinal chemistry to identify disease targets and advance potential therapeutic programs.

Odyssey’s research and development activities are centered on small-molecule medicines designed to address genetically validated targets and specific disease mechanisms.

See Also